Serious herpes zoster in rheumatoid arthritis under anti-interleukin-6 receptor antibody.

Zuzana Kubandova,S. Mathieu,Claire Pourtier,M. Soubrier

DOI: https://doi.org/10.1016/j.jbspin.2010.07.009

2010-12-01

Abstract:

What problem does this paper attempt to address?

The evolution of T-cell receptor repertoire in different stages of non-small cell lung cancer

Ziqi Jia,Yadong Wang,Xiaoying Yang,Pancheng Wu,Yanyu Wang,Yang Song,Huihui Xu,Dejian Gu,Rongrong Chen,Jin Li,Xuefeng Xia,Zhongxing Bing,Lei Cao,Zhili Cao,Peng Liu,Huaxia Yang,Shanqing Li,Naixin Liang

DOI: https://doi.org/10.21203/rs.3.rs-26421/v1

2020-01-01

Abstract:Abstract Background The intricate relationship between the tumor and host was not well understood, and antigen-specific T cell is fundamental in understanding the interaction. TCR repertoire analysis which described TCR clonotypes and TCR numbers has shown that TCRs with high frequency was tumor-specific T cells, while others might be ‘bystander’ T cells within tumors. However, how these “expanded” tumor-specific T cells was selected during the tumor development was not clear. Methods We retrospectively analyzed TCR sequencing and mutation sequencing results from 144 non-small cell lung cancer (NSCLC) patients. Results A rich TCR repertoire comprising thousands of different TCR sequences was identified in all stages of NSCLC, with most TCR clonotypes presented at low frequency. Interestingly, Stage IV NSCLC tumors contain more expanded TCRs as compared to earlier stages, however, lymph node metastasis or tumor size had little impact on expanded TCRs. Moreover, accumulation of mutations did not significantly change the number of TCR clonotypes, however, EGFR mutant patients had significantly lower while KRAS mutant patients had significantly higher number of TCR clonotypes especially in terms of those “expanded” TCRs. Conclusions In summary, T cells in the tumor microenvironment were gradually activated with tumor development. Critical events such as distal metastases and generation of EGFR or KRAS mutations might be the major factors affecting the changing of tumor-specific T cells in the tumor microenvironment.
Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues

Qikang Hu,Meredith L Frank,Yang Gao,Liyan Ji,Muyun Peng,Chen Chen,Bin Wang,Yan Hu,Zeyu Wu,Jina Li,Lu Shu,Qiongzhi He,Yingqian Zhang,Xuefeng Xia,Jianjun Zhang,Xin Yi,Alexandre Reuben,Fenglei Yu

DOI: https://doi.org/10.1080/2162402X.2023.2233399

2023-10-20

OncoImmunology

Abstract:Background: A better understanding of T cells in lung cancer and their distribution across tumor-adjacent lungs and peripheral blood is needed to improve efficacy and minimize toxicity from immunotherapy to lung cancer patients. Methods: Here, we performed CDR3β TCR sequencing of 136 samples from 20 patients with early-stage NSCLC including peripheral blood mononuclear cells, tumors, tumor edges (<1 cm from tumor), as well as adjacent lungs 1 cm, 2 cm, 5 cm, and 10 cm away from the tumor to gain insight into the spatial heterogeneity of T cells across the lungs in patients with NSCLC. PD-L1, CD4, and CD8 expression was assessed using immunohistochemical staining, and genomic features were derived by targeted sequencing of 1,021 cancer-related genes. Multiplex immunohistochemistry against PD-1, CTLA4, LAG3, and TIM3 was performed on four patients to assess T cell exhaustion. Results: Our study reveals a decreasing gradient in TIL Tumor Infiltrating Lymphocytes homology with tumor edge, adjacent lungs, and peripheral blood but no discernible distance-associated patterns of T cell trafficking within the adjacent lung itself. Furthermore, we show a decrease in pathogen-specific TCRs in regions with high T cell clonality and PD-L1 expression. Conclusions: Exclusion in T exhaustion cells at play across the lungs of patients with NSCLC may potentially be the mechanism for lung cancer occurrence.
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing

Xinyi Guo,Yuanyuan Zhang,Liangtao Zheng,Chunhong Zheng,Jintao Song,Qiming Zhang,Boxi Kang,Zhouzerui Liu,Liang Jin,Rui Xing,Ranran Gao,Lei Zhang,Minghui Dong,Xueda Hu,Xianwen Ren,Dennis Kirchhoff,Helge Gottfried Roider,Tiansheng Yan,Zemin Zhang

DOI: https://doi.org/10.1038/s41591-018-0045-3

Abstract:Cancer immunotherapies have shown sustained clinical responses in treating non-small-cell lung cancer1-3, but efficacy varies and depends in part on the amount and properties of tumor infiltrating lymphocytes4-6. To depict the baseline landscape of the composition, lineage and functional states of tumor infiltrating lymphocytes, here we performed deep single-cell RNA sequencing for 12,346 T cells from 14 treatment-naïve non-small-cell lung cancer patients. Combined expression and T cell antigen receptor based lineage tracking revealed a significant proportion of inter-tissue effector T cells with a highly migratory nature. As well as tumor-infiltrating CD8+ T cells undergoing exhaustion, we observed two clusters of cells exhibiting states preceding exhaustion, and a high ratio of "pre-exhausted" to exhausted T cells was associated with better prognosis of lung adenocarcinoma. Additionally, we observed further heterogeneity within the tumor regulatory T cells (Tregs), characterized by the bimodal distribution of TNFRSF9, an activation marker for antigen-specific Tregs. The gene signature of those activated tumor Tregs, which included IL1R2, correlated with poor prognosis in lung adenocarcinoma. Our study provides a new approach for patient stratification and will help further understand the functional states and dynamics of T cells in lung cancer.
Association of the T-cell Receptor Landscape with Survival in Non-Small Cell Lung Cancer.

Alexandre Reuben,Rachel Gittelman,Jiexin Zhang,Kelly Quek,Luis M. Vence,Carmen Behrens,Runzhe Chen,Junya Fujimoto,Chi-Wan Chow,Xifeng Wu,James Patrick Allison,Padmanee Sharma,Jianhua Zhang,J. Jack Lee,Boris Sepesi,Don Lynn Gibbons,John Heymach,Andrew Futreal,Ignacio Ivan Wistuba,Jianjun Zhang

DOI: https://doi.org/10.1200/jco.2018.36.5_suppl.140

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:140 Background: Non-small cell lung cancer (NSCLC) is characterized by a high mutational load. Accordingly, it is also among the tumor types which respond best to immune checkpoint blockade, likely through its ability to enhance the anti-tumor T cell response. However, the lung is constantly exposed to the outside environment, which may result in a continuous state of inflammation targeting pathogens rather than tumor cells. Therefore, a greater understanding of the T cell receptor (TCR) landscape and phenotypes across normal lung and tumor is warranted. Methods: Here, we performed sequencing of the CDR3 variable region of the beta chain of the TCR as well as whole exome sequencing on peripheral blood, normal lung and tumor in 235 NSCLC patients. We further analyzed the immune microenvironment by Cytometry by Time-of-Flight (CyTOF) in 10 NSCLC patients with paired normal lung and tumor. Results: Comparison of the TCR repertoire showed 9% (up to 15%) of T cells were shared between normal lung and tumor, though the most dominant were generally shared (up to 95%). Interestingly, T cell clonality was higher in the normal lung than tumor in almost all patients (89%, p < 0.0001) suggesting potential differences in the ongoing immune response in different regions of the lung. A substantial number of non-synonymous exonic mutations (NSEM) were detected in tumors (average = 566 NSEM) but also in the normal lung (average = 156 NSEM), with many shared (up to 45.6%). CyTOF confirmed marked differences in the immune microenvironment, including higher frequency of VISTA+ antigen-presenting cells in the tumor (p = 0.04). Finally, analysis of clinicopathological attributes revealed a greater T cell diversity in the periphery in patients with increased overall survival (OS, p = 0.001), while patients with a more similar normal lung/tumor T cell repertoire showed decreased OS (p = 0.028). Conclusions: These results suggest that a substantial proportion of infiltrating T cells in NSCLC tumors may be lung-resident T cells associated with response to environmental factors. However, normal lung and NSCLC tumors carry T cells of distinct phenotypes, which highlights differences in the ongoing antigenic response within the lung.
Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression

Yingyi Wang,Na Zhou,Rui Zhu,Xiaoyuan Li,Zhao Sun,Yang Gao,Wei Liu,Changting Meng,Yuping Ge,Chunmei Bai,Taisheng Li,Hongsheng Liu

DOI: https://doi.org/10.1186/s12890-021-01636-x

IF: 3.1

2021-09-06

BMC Pulmonary Medicine

Abstract:Abstract Background Treatment for non-small cell lung cancer (NSCLC) has greatly improved in recent years. However, noninvasive early screening for carcinogenesis and progression unclear. The aim of this study was to explore the predictive value of peripheral blood immune cells in untreated NSCLC patients. Methods We retrospectively enrolled 305 untreated NSCLC patients and 132 healthy participants from February 2016 to August 2019 in Peking Union Medical College Hospital. Immune cell levels were determined by flow cytometry and routine blood tests. Results NSCLC patients had lower levels of T lymphocytes, NK cells, CD8+ T cells, naïve CD4+/CD4+, naïve CD4+ T cells and higher levels of CD4+ T cells, memory CD4+/CD4+ T cells, memory CD4+ T cells, CD4+CD28+/CD4+ T cells, CD4+CD28+ T cells, CD8+CD28+/CD8+ T cells, CD8+HLA-DR+/CD8+ T cells, CD8+HLA-DR+ T cells T cells, CD8+CD38+/CD8+ T cells, CD8+CD38+ T cells and CD4+/CD8+ T cells than those in controls. The percentages of specific lymphocyte subtypes were significantly different in cancer patients versus healthy individuals. For instance, cancer patients had lower levels of B cells, CD4+ T cells, naïve CD4+/CD4+ T cells, naïve CD4+ T cells, CD4+CD28+ T cells, CD8+CD28+ T cells and higher levels of NK cells, white blood cells (WBC), monocytes, neutrophils, eosinophils, basophils, monocytes to lymphocyte ratio (MLR), neutrophils to lymphocyte ratio (NLR), eosinophil to lymphocyte ratio (ELR), basophil to lymphocyte ratio (BLR), and blood platelet to lymphocyte ratio (PLR). Conclusions Abnormal T cell levels can be used as an independent predictive biomarker for noninvasive early screening in NSCLC occurrence and progression.

respiratory system
Characterization of T-cell Receptor Repertoire and Correlation with Tumor Mutational Landscape in Lung Cancer.

Wei Guo,Huaichao Luo,Linfeng Dong,Yanqing Zhou,Zuoquan Yang,Jialin Zhang,Shuxiong Zhou,Hui Li,Yuanyuan Liu,Dongsheng Wang,Shifu Chen

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.2577

IF: 45.3

2024-01-01

Journal of Clinical Oncology

Abstract:2577 Background: T-cell receptor (TCR) repertoire represents an overall immune condition which is closely related to pathogens- or tumor-associated T cell responses. Increasing evidence suggests that TCR repertoire is expected to undergo cancer-specific changes during tumorigenesis, supporting that TCR characteristics can serve as novel markers to indicate early cancer progression. Here, we performed a systematic T cell repertoire analysis in lung cancer. We identified cancer-enriched TCR signatures and constructed a comprehensive lung cancer database integrating TCR diversity, tumor mutational profiles, immune markers expression and HLA genotypes. Methods: A total of 988 tissue samples and 3,360 blood samples were obtained from patients with lung cancer, in addition to 2,699 blood samples from healthy individuals. Multiplex-PCR-based sequencing of the CDR3 regions of TCR-β chains was applied to the tissue and blood samples. TCR repertoires were analyzed using MiXCR and VDJtools. Whole exome sequencing was performed on partial tumor tissues to profile the mutational landscape and HLA genotypes. An in-house pipeline, considering the frequency and distribution of CDR3, was utilized to identify cancer-enriched CDR3 sequences. The PD-L1 expression was evaluated and quantified using CPS. Furthermore, an enrich score was developed to measure the content of cancer-related TCRs by aligning against the built cancer-enriched CDR3 dataset. Spearman's rank correlation was used to assess relationships between variables. Results: Lung cancer exhibited significantly lower Shannon index, Simpson index and evenness index in TCR repertoire (p<0.001), both in tissue and blood samples, when compared with healthy blood samples. Approximate 3% T-cell clonotypes within lung tissues were detected in blood TCR repertoires. A correlation was observed between the decreased TCR diversity and a higher tumor mutational burden (TMB)(r = -0.15, p < 0.01), as well as a higher variant allele frequency (VAF) (r = -0.19, p < 0.01). In this study, 3,652 and 3,840 CDR3 sequences were identified to be enriched in lung cancer tissue and blood respectively. A significant difference in cancer-enriched score was observed between cancer and healthy TCR repertoires (p < 0.001). The cancer-enriched score showed a significant positive correlation with TMB, particularly in TP53- mutant tumors (r = 0.27, p < 0.001). A higher CPS (PD-L1) was associated with a higher cancer-enriched score (r = 0.18 ,p < 0.01). Conclusions: Cancer-related T-cell clonotypes in the tumor microenvironment and peripheral blood informs the changes in anti-tumor responses, supporting the potential application of TCR signatures in early cancer detection. This study identified the lung cancer-related TCR signatures and provided a comprehensive lung cancer TCR database, revealing the relationship between TCR characteristics and mutational profiles. Clinical trial information: ChiCTR2200055761.
Functional status and spatial interaction of T cell subsets driven by specific tumor microenvironment correlate with recurrence of non-small cell lung cancer

Liying Yang,Wei Zhang,Jujie Sun,Guanqun Yang,Siqi Cai,Fenghao Sun,Ligang Xing,Xiaorong Sun

DOI: https://doi.org/10.3389/fimmu.2022.1022638

IF: 7.3

2023-01-04

Frontiers in Immunology

Abstract:Background The anti-tumoral or pro-tumoral roles of CD4 + and CD8 + T cells typify the complexity of T cell subsets function in cancer. In the non-small cell lung cancer (NSCLC), the density and topology of distinct T cell phenotypes at the tumor center (TC) versus the invasive margin (IM) are largely unknown. Here, we investigated T cell subsets density and distribution within TC and IM regions in NSCLC and its impact on the prognosis. Methods We performed multiplex immunofluorescence using a tissue microarray of samples from 99 patients with locally advanced NSCLC to elucidate the distributions of tumor cell, T cell subpopulations (CD4/conventional CD4/regulatory CD4/CD8/cytotoxic CD8/pre-dysfunctional CD8/dysfunctional CD8), microvessel density (MVD), cancer-associated fibroblasts (CAFs) and hypoxia-inducible factor-1α (HIF-1α) in TC and IM tissues. Cell-to-cell nearest neighbor distances and interactions were analyzed using the phenoptrreports R package. Cox regression was used to evaluate the associations between T cell subsets density and proximity to tumor cells and recurrence-free survival (RFS). Correlations between different cell subsets were examined by Spearman’s or Kruskal-Wallis tests. Results In the locally advanced NSCLC, the proportion of tumor cells and CAFs in IM is lower than in the TC, while MVD, CD4 + , and CD8 + T lymphocytes were increased, and tumor cells were closer to T lymphocytes and their subsets. The density and proximity of CD4 + and CD8 + T cells in the TC and IM regions were not associated with RFS, but in the IM area, increased density of dysfunctional CD8 and closer regulatory CD4 to tumor cells were independent risk factors for recurrence (HR were 3.536 and 2.884, respectively), and were positively correlated with HIF-1α + CD8 (r = 0.41, P = 0.000) and CAFs ( P = 0.017), respectively.s Conclusions In locally advanced NSCLC, the functional status of T cells in the IM region is closely related to recurrence. The density of dysfunctional CD8 and the proximity of regulatory CD4 to tumor cells were independent risk factors for recurrence, and are positively correlated with the hypoxia response of CD8 + T cells and CAFs. Targeting hypoxia or CAFs is expected to further sensitize therapy.

immunology
Single-Cell Transcriptomics of Immune Cells Reveal Diversity and Exhaustion Signatures in Non-Small-Cell Lung Cancer

Ying Zhao,Qilin Zhang,Kailin Tu,Yanmei Chen,Yuxuan Peng,Yinyun Ni,Guonian Zhu,Cheng Cheng,Yangqian Li,Xue Xiao,Chunyan Yu,Keying Lu,Yaxin Chen,Chengpin Li,Jun Tang,Gang Wang,Wenxin Luo,Wengeng Zhang,Guowei Che,Weimin Li,Zhoufeng Wang,Dan Xie

DOI: https://doi.org/10.3389/fimmu.2022.854724

IF: 7.3

2022-07-07

Frontiers in Immunology

Abstract:Understanding immune cell phenotypes in the tumor microenvironment (TME) is essential for explaining and predicting progression of non-small cell lung cancer (NSCLC) and its response to immunotherapy. Here we describe the single-cell transcriptomics of CD45 + immune cells from tumors, normal tissues and blood of NSCLC patients. We identified three clusters of immune cells exerting immunosuppressive effects: CD8 + T cells with exhausted phenotype, tumor-associated macrophages (TAMs) with a pro-inflammatory M2 phenotype, and regulatory B cells (B regs) with tumor-promoting characteristics. We identified genes that may be mediating T cell phenotypes, including the transcription factors ONECUT2 and ETV4 in exhausted CD8 + T cells, TIGIT and CTL4 high expression in regulatory T cells. Our results highlight the heterogeneity of CD45 + immune cells in the TME and provide testable hypotheses about the cell types and genes that define the TME.

immunology
Deciphering the Immune–Tumor Interplay During Early-Stage Lung Cancer Development via Single-Cell Technology

Wei-Wei Chen,Wei Liu,Yingze Li,Jun Wang,Yijiu Ren,Guangsuo Wang,Chang Chen,Hanjie Li

DOI: https://doi.org/10.3389/fonc.2021.716042

IF: 4.7

2022-01-03

Frontiers in Oncology

Abstract:Lung cancer is the leading cause of cancer-related death worldwide. Cancer immunotherapy has shown great success in treating advanced-stage lung cancer but has yet been used to treat early-stage lung cancer, mostly due to lack of understanding of the tumor immune microenvironment in early-stage lung cancer. The immune system could both constrain and promote tumorigenesis in a process termed immune editing that can be divided into three phases, namely, elimination, equilibrium, and escape. Current understanding of the immune response toward tumor is mainly on the “escape” phase when the tumor is clinically detectable. The detailed mechanism by which tumor progenitor lesions was modulated by the immune system during early stage of lung cancer development remains elusive. The advent of single-cell sequencing technology enables tumor immunologists to address those fundamental questions. In this perspective, we will summarize our current understanding and big gaps about the immune response during early lung tumorigenesis. We will then present the state of the art of single-cell technology and then envision how single-cell technology could be used to address those questions. Advances in the understanding of the immune response and its dynamics during malignant transformation of pre-malignant lesion will shed light on how malignant cells interact with the immune system and evolve under immune selection. Such knowledge could then contribute to the development of precision and early intervention strategies toward lung malignancy.

oncology
[Effect of growing location on sensory properties and nutritional characteristics of black beans (Phaseolus vulgaris L.)].

J. Castellanos,H. Guzmán-Maldonado,E. D. de Mejia,J. Acosta-Gallegos

1995-03-01

Archivos Latinoamericanos de Nutrición

Abstract:The present research consisted of an evaluation of five genotypes harvested from six growing locations. Variables of sensory properties, cooking quality and nutritional characteristics were determined. Genotype with longer cooking time was BV which also present hard shell. Those of shorter cooking time were FMB and PV. In Calera frosting during pod filling, drastically reduced cooking time, sensory properties and tannins. Taking this location off, the analysis show little effect of genotype or growing location in regard to determined properties. The genotypes with lower content of tannins were PV and BV. The content of lectins were in general low for all samples and the diferences between genotypes were not statistically significant (p<0.05) but they did for growing location.
MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer

A. Reuben,J. Zhang,R. Gittelman,S. Chiou,J. Li,J. Fujimoto,C. Behrens,F. Kheradmand,C. Chow,C. Bernatchez,A.K. Eterovic,S. Benzeno,M. Vignali,X. Xifeng Wu,Y. Ye,T. Cascone,R. Herbst,S. Swisher,H. Kadara,C. Moran,P. Scheet,A. Vaporciyan,B. Sepesi,D. Gibbons,H. Robins,P. Hwu,J. Heymach,P. Sharma,J. Allison,J. Lee,M. Davis,I. Wistuba,P.A. Futreal

DOI: https://doi.org/10.1016/j.jtho.2019.08.589

IF: 20.121

2019-01-01

Journal of Thoracic Oncology

Abstract:Non-small cell lung cancer (NSCLC) exhibits a high mutational burden. As a result, patients afflicted by this tumor type experience greater responses to immune checkpoint blockade. This is largely due to the ability of T cells to destroy tumor cells on the basis of antigens recognized by their T cell receptor (TCR). However, the lungs are exposed to carcinogens and pathogens which can also trigger a T cell response distinct from cancer. Therefore, a better understanding of the T cell repertoire in the lungs is needed to improve upon the success of current immunotherapies in NSCLC. We obtained peripheral blood, tumors, and adjacent uninvolved lungs from a cohort of 236 early stage NSCLC patients. Whole exome sequencing, RNA microarray, immunohistochemistry (CD3, CD4, CD8, CD57, CD68, FoxP3, CD45RO, GzmB, PD-1, and PD-L1) and T cell repertoire sequencing were performed in NSCLC patients and lungs from organ donors and COPD patients. Antigen specificity was predicted using the Grouping of Lymphocyte Interactions by Paratope Hotspot (GLIPH) algorithm. Single cell TCR and RNA sequencing as well as sequencing of the virome are underway. Clonality was associated with CD8 T cells (r=0.31; p=0.0003), GzmB (r=0.29; p=0.001) and IFN-γ (r=0.52; p<0.0001) production as well as with tumor mutational burden (r=0.19; p=0.015), HLA-B (r=0.29; p=0.0005) and β2-m expression (r=0.20; p=0.018). Patients with classical EGFR mutations exhibited lower T cell clonality (p=0.003) even after adjustment for TMB, highlighting the impact of this driver mutation on the T cell response. Surprisingly, clonality was higher in the adjacent uninvolved lung than tumor (p<0.0001), suggesting an active antigenic response outside the tumor. Comparison of the composition of the T cell repertoire between the uninvolved lung and tumor revealed 57% of the top 100 T cells in the tumor were also found in the adjacent normal lung, highlighting certain parallels in the ongoing antigenic responses. Deeper analysis suggested that shared T cells may have been reactive against mutations shared between the normal lung and tumor (r=0.23, p=0.028) or viruses (p<0.0001). Accordingly, patients with a more reactive T cell repertoire outside the tumor (i.e. bystanders) exhibited shorter disease-free survival (p=0.036) suggesting these responses against shared mutations and/or viruses may detract from the anti-tumor T cell response. Our findings highlight the importance of understanding the specificity of the T cell repertoire in the lungs in patients with NSCLC treated with immunotherapy. As a high proportion of bystander T cells appear to reside in the lungs, their reactivation could contribute to the impaired responses and/or increased toxicity observed in certain patients with NSCLC treated with immunotherapy.
Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer

Huaxia Yang,Yadong Wang,Ziqi Jia,Yanyu Wang,Xiaoying Yang,Pancheng Wu,Yang Song,Huihui Xu,Dejian Gu,Rongrong Chen,Xuefeng Xia,Zhongxing Bing,Chao Gao,Lei Cao,Shanqing Li,Zhili Cao,Naixin Liang

DOI: https://doi.org/10.3389/fonc.2021.537735

IF: 4.7

2021-03-11

Frontiers in Oncology

Abstract:Lung cancer is the leading cause of cancer-related deaths worldwide, and its occurrence is related to the accumulation of gene mutations and immune escape of the tumor. Sequencing of the T-cell receptor (TCR) repertoire can reveal the immunosurveillance status of the tumor microenvironment, which is related to tumor escape and immunotherapy. This study aimed to determine the characteristics and clinical significance of the TCR repertoire in lung cancer. To comprehensively profile the TCR repertoire, results from high-throughput sequencing of samples from 93 Chinese patients with lung cancer were analyzed. We found that the TCR clonality of tissues was related to smoking, with higher clonality in patients who had quit smoking for less than 1 year. As expected, TCR clonality was correlated with stages: patients with stage IV disease showed higher clonality than others. The correlation between TCR repertoire and epidermal growth factor receptor (EGFR) status was also investigated. Patients with EGFR non-L858R mutations showed higher clonality and a lower Shannon index than other groups, including patients with EGFR L858R mutation and wild-type EGFR . Furthermore, we analyzed the TCR similarity metrics—that is, the TCR shared between postoperative peripheral blood and tissue of patients with non-distant metastasis of lung cancer. A similar trend was found, in which patients with EGFR L858R mutations had lower overlap index (OLI) and Morisita index (MOI) scores. Moreover, the OLI showed a positive correlation with several clinical characteristics, including the tumor mutational burden of tissues and the maximum somatic allele frequency of blood; OLI showed a negative correlation with the ratio of CD4+CD28+ in CD4+ cells and the ratio of CD8+CD28+ in CD8+ cells. In conclusion, TCR clonality and TCR similarity metrics correlated with clinical characteristics of patients with lung cancer. Differences in TCR clonality, Shannon index, and OLI across EGFR subtypes provide information to improve understanding about varied responses to immunotherapy in patients with different EGFR mutations.

oncology
Functionally Impaired Follicular Helper T Cells Induce Regulatory B Cells and CD14(+) Human Leukocyte Antigen-Dr- Cell Differentiation in Non-Small Cell Lung Cancer

Liannv Qiu,Qinhua Yu,Yonglie Zhou,Sujie Zheng,Jiaojiao Tao,Qian Jiang,Guorong Yuan

DOI: https://doi.org/10.1111/cas.13836

IF: 5.7

2018-01-01

Cancer Science

Abstract:Non-small cell lung cancer (NSCLC) represents one of the most common and aggressive cancers worldwide, as it typically displays irreversible progression and poor prognosis. Interaction between programmed death 1 (PD-1) and its ligand, PD-L1, plays important roles in tumor immunology. Follicular helper T (Tfh) cells have characteristically high PD-1 expression; thus, in the present study, we investigated the role of circulating Tfh cells and their correlation with disease-free survival after tumor resection in NSCLC. We found significantly higher number of Tfh cells but lower serum interleukin (IL)-21 levels in NSCLC patients, especially in those with advanced stage (III and IV), indicating that the function of Tfh cells to produce IL-21 was impaired. Further analysis showed that the increase in Tfh cells was attributable to an expansion of the PD-1(+)-Tfh2 and PD-1(+)-Tfh17 subtypes. Functional analysis showed that Tfh cells from NSCLC patients induced the differentiation of regulatory B cells and CD14(+) human leukocyte antigen (HLA)-DR- cells. Interestingly, the number of Tfh1 subtypes in NSCLC patients was negatively correlated with disease-free survival after tumor resection. In short, the high number and abnormal function of Tfh cells could cause further immunosuppression and lead to tumor development in NSCLC. Rescuing Tfh functions therefore represents a potential therapeutic strategy in NSCLC.
Heterogeneity of lymphocyte subsets in predicting immune checkpoint inhibitor treatment response in advanced lung cancer: an analysis across different pathological types, therapeutic drugs, and age groups

Chuanwang Miao,Yuanji Chen,Hao Zhang,Wei Zhao,Cunliang Wang,Zeliang Ma,Shan Zhu,Xudong Hu

DOI: https://doi.org/10.21037/tlcr-24-109

2024-06-30

Abstract:Background: Immune checkpoint inhibitor (ICI) has become pivotal in the treatment of advanced lung cancer, yet the absence of reliable biomarkers for assessing treatment response poses a significant challenge. This study aims to explore the predictive value of various lymphocyte subsets in different lung cancer subtypes, thus potentially identifying novel biomarkers to improve ICI treatment stratification and outcomes. Methods: We conducted a retrospective analysis of 146 stage III or IV lung cancer patients undergoing ICI treatment. The study focused on exploring the relationship between various lymphocyte subsets and the efficacy of ICIs, aiming to determine their predictive value for post-treatment outcomes. Results: Subgroup analysis revealed a positive correlation (P=0.01) between lower CD3+CD8+ T lymphocyte levels and treatment response in squamous cell carcinoma patients. However, no significance was observed in lung adenocarcinoma patients. Additionally, the predictive ability of lymphocyte subsets for different immunotherapy drugs varies. In individuals receiving anti-programmed cell death ligand 1 (PD-L1) treatment, a lower CD3+CD8+ T lymphocyte levels is significantly associated with a positive treatment outcome (P=0.002), while there is no difference for programmed death 1 (PD-1) drugs. Among patients under 60, higher expression of CD3+CD4+ T lymphocytes (P=0.03) combined with lower CD3+CD8+ T lymphocyte levels (P=0.006) showed a statistically significant association with improved treatment response. However, in patients aged over 60, no discernible correlation was ascertained between lymphocyte subsets and therapeutic response. Through prognostic analysis, two distinct lymphocyte subsets were identified, both exerting considerable impact on progression-free survival subsequent to ICIs treatment: CD3+CD4+ T lymphocytes [hazard ratio (HR) =0.50, P=0.006] and CD3+CD8+ T lymphocytes (HR =1.78, P=0.02). Conclusions: Our findings underscore the significant heterogeneity in the predictive value of distinct lymphocyte subsets for lung cancer patients undergoing ICI treatment. These findings are particularly salient when considering various pathological types, immunotherapeutic agents, and patient age groups.
Comprehensive Analysis of T-cell Receptor Sequencing in Resectable Squamous Cell Lung Cancer Patients with Neoadjuvant Therapy of PD-1 Inhibitor and Chemotherapy.

Yuan Feng,Shanshan Xiao,Wei Sun,Yuanyuan Ma,Yang Hong,Yue Pu,Rui Lin,Tao Wang,Dongmei Lin,Yue Yang

DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.e21012

IF: 45.3

2020-01-01

Journal of Clinical Oncology

Abstract:e21012 Background: Cancer therapies alter the tumor microenvironment such as the infiltration of T cells. Neoadjuvant therapy to squamous cell lung cancer patients using PD-1 inhibitor expands specific T cell clones. However, the T cell clones and diversity in tumors and lymph nodes according to different neoadjuvant settings remain largely unknown. In this study, we used T-cell receptor (TCR) sequencing technology to investigate the TCR clonotypes and diversities in squamous cell NSCLC patients who received neoadjuvant chemotherapy and PD-1 inhibitor plus chemotherapy. Methods: Tumor tissues, non-metastatic lymph nodes (NMLN)s, and available metastatic lymph nodes (MLNs) were collected from two patient groups. Each group enrolled three patients who received either neoadjuvant chemotherapy or PD-1 inhibitor plus chemotherapy. DNA samples were harvested and processed for multiplex PCR for the third complementary determining region (CDR3) of TCR-β chain followed by the next generation sequencing analysis. Differences of the CDR3 clonotypes and clonal diversities were analyzed by bioinformatics tools including the Mixcr software. Results: For all the six patients, TCR clonotypes in the tumor tissues were found to be fewer than those from the lymph nodes in the same patient, consistent with a hypothesis that most of the tumor infiltrated T cells after therapy derive from the lymph nodes. Some clonotypes among the top 10 highest frequencies were found in different samples from the same patient, further supporting the lymph node origin of the tumor infiltrating T cells after therapies. Interestingly, TCR clonal diversity was higher in the NMLNs compared with the MLNs, but clonotype overlap with tumor tissues was higher in the MLNs than NMLNs; these results could imply that TCR clonotypes in the primary lymph node were more stimulated. Additionally, there were very few clonotypes shared between different patients, indicating the heterogeneity of immune response for different individuals. Due to the limited sample size, we could not find the systemic difference between the two patient groups. Conclusions: TCR sequencing technology can detect the CDR3 clonotypes in tumor tissues and lymph nodes of cancer patients, providing new opportunities for revealing patients' response to chemotherapy and immunotherapy. Further analysis will be performed to investigate TCR clonotype differences caused by immunotherapy.
Cellular dynamics in tumour microenvironment along with lung cancer progression underscore spatial and evolutionary heterogeneity of neutrophil

Haoxin Peng,Xiangrong Wu,Shaopeng Liu,Miao He,Chenshuo Tang,Yaokai Wen,Chao Xie,Ran Zhong,Caichen Li,Shan Xiong,Jun Liu,Hongbo Zheng,Jianxing He,Xu Lu,Wenhua Liang

DOI: https://doi.org/10.1002/ctm2.1340

IF: 8.554

2023-07-27

Clinical and Translational Medicine

Abstract:1. The cellular composition, spatial location, molecular and functional changes in primary tumour and paired tumour‐draining lymph node microenvironments along with non‐small cell lung cancer progression were comprehensively profiled. 2. Tumour‐associated neutrophils (TANs) showed unique spatial and temporal‐dependent prognostic effects. 3. The immunoregulatory roles and evolutionary heterogeneity of TANs during lymphatic metastasis were demonstrated. Background The cellular dynamics in the tumour microenvironment (TME) along with non‐small cell lung cancer (NSCLC) progression remain unclear. Methods Multiplex immunofluorescence test detecting 10 immune‐related markers on 553 primary tumour (PT) samples of NSCLC was conducted and spatial information in TME was assessed by the StarDist depth learning model. The single‐cell transcriptomic atlas of PT (n = 4) and paired tumour‐draining lymph nodes (TDLNs) (n = 5 for tumour‐invaded, n = 3 for tumour‐free) microenvironment was profiled. Various bioinformatics analyses based on Gene Expression Omnibus, TCGA and Array‐Express databases were also used to validate the discoveries. Results Spatial distances of CD4+ T cells–CD38+ T cells, CD4+ T cells–neutrophils and CD38+ T cells–neutrophils prolonged and they were replaced by CD163+ macrophages in PT along with tumour progression. Neutrophils showed unique stage and location‐dependent prognostic effects. A high abundance of stromal neutrophils improved disease‐free survival in the early‐stage, whereas high intratumoural neutrophil infiltrates predicted poor prognosis in the mid‐to‐late‐stage. Significant molecular and functional reprogramming in PT and TDLN microenvironments was observed. Diverse interaction networks mediated by neutrophils were found between positive and negative TDLNs. Five phenotypically and functionally heterogeneous subtypes of tumour‐associated neutrophil (TAN) were further identified by pseudotime analysis, including TAN‐0 with antigen‐presenting function, TAN‐1 with strong expression of interferon (IFN)‐stimulated genes, the pro‐tumour TAN‐2 subcluster, the classical subset (TAN‐3) and the pro‐inflammatory subtype (TAN‐4). Loss of IFN‐stimulated signature and growing angiogenesis activity were discovered along the transitional trajectory. Eventually, a robust six neutrophil differentiation relevant genes‐based model was established, showing that low‐risk patients had longer overall survival time and may respond better to immunotherapy. Conclusions The cellular composition, spatial location, molecular and functional changes in PT and TDLN microenvironments along with NSCLC progression were deciphered, highlighting the immunoregulatory roles and evolutionary heterogeneity of TANs.

oncology,medicine, research & experimental
Comprehensive T cell repertoire characterization of non-small cell lung cancer

Alexandre Reuben,Jiexin Zhang,Shin-Heng Chiou,Rachel M. Gittelman,Jun Li,Won-Chul Lee,Junya Fujimoto,Carmen Behrens,Xiaoke Liu,Feng Wang,Kelly Quek,Chunlin Wang,Farrah Kheradmand,Runzhe Chen,Chi-Wan Chow,Heather Lin,Chantale Bernatchez,Ali Jalali,Xin Hu,Chang-Jiun Wu,Agda Karina Eterovic,Edwin Roger Parra,Erik Yusko,Ryan Emerson,Sharon Benzeno,Marissa Vignali,Xifeng Wu,Yuanqing Ye,Latasha D. Little,Curtis Gumbs,Xizeng Mao,Xingzhi Song,Samantha Tippen,Rebecca L. Thornton,Tina Cascone,Alexandra Snyder,Jennifer A. Wargo,Roy Herbst,Stephen Swisher,Humam Kadara,Cesar Moran,Neda Kalhor,Jianhua Zhang,Paul Scheet,Ara A. Vaporciyan,Boris Sepesi,Don L. Gibbons,Harlan Robins,Patrick Hwu,John V. Heymach,Padmanee Sharma,James P. Allison,Veera Baladandayuthapani,Jack J. Lee,Mark M. Davis,Ignacio I. Wistuba,P. Andrew Futreal,Jianjun Zhang

DOI: https://doi.org/10.1038/s41467-019-14273-0

IF: 16.6

2020-01-30

Nature Communications

Abstract:Abstract Immunotherapy targeting T cells is increasingly utilized to treat solid tumors including non-small cell lung cancer (NSCLC). This requires a better understanding of the T cells in the lungs of patients with NSCLC. Here, we report T cell repertoire analysis in a cohort of 236 early-stage NSCLC patients. T cell repertoire attributes are associated with clinicopathologic features, mutational and immune landscape. A considerable proportion of the most prevalent T cells in tumors are also prevalent in the uninvolved tumor-adjacent lungs and appear specific to shared background mutations or viral infections. Patients with higher T cell repertoire homology between the tumor and uninvolved tumor-adjacent lung, suggesting a less tumor-focused T cell response, exhibit inferior survival. These findings indicate that a concise understanding of antigens and T cells in NSCLC is needed to improve therapeutic efficacy and reduce toxicity with immunotherapy, particularly adoptive T cell therapy.

multidisciplinary sciences
Immunomodulatory Effects of Chemotherapy on Blood Lymphocytes and Survival of Patients with Advanced Non-Small Cell Lung Cancer

Mohanad Aldarouish,Xiangyu Su,Jianbing Qiao,Chanchan Gao,Yan Chen,Anwei Dai,Tianyu Zhang,Yongqian Shu,Cailian Wang

DOI: https://doi.org/10.1177/2058738419839592

2019-01-01

International Journal of Immunopathology and Pharmacology

Abstract:A better understanding of the immune profile of non-small cell lung cancer (NSCLC) and the immunomodulatory impact of chemotherapy is essential to develop current therapeutic approaches. Herein, we collected peripheral blood from 20 healthy donors and 50 patients with advanced NSCLC, before and after chemotherapy, followed by phenotypic analysis of lymphocyte subsets and assessment of the correlation between their post-chemotherapy levels and progression-free survival (PFS). Results showed that, before chemotherapy, the levels of CD8+ lymphocytes, PD-1+CD4+, Th2, and Th17 cells were elevated in patients’ peripheral blood, in contrast to natural killer (NK) cells and Th1 cells. Besides, there was no remarkable difference in the frequency of PD-1+CD8+ cells between patients and healthy controls. After chemotherapy, the levels of CD8+ lymphocytes, NK, Th2, Th17, and Treg were declined, in contrast to the level of Th1 cells which was markedly increased. Importantly, chemotherapy had no impact on the frequencies of PD-1+CD8+ and PD-1+CD4+ cells. PFS was significantly better in patients with low percentage of PD-1+CD4+ T cells than those with high percentage. Patients with high content of Th1 cells showed longer PFS than those with low content. The low percentages of Th17 and Treg cells were correlated with longer PFS, even though the difference did not reach statistical significance. In conclusion, the imbalance of lymphocyte subsets is a hallmark of NSCLC. Furthermore, the high level of PD-1+CD4+ cells plays a crucial role in the progression of NSCLC and could be used as a prognostic marker; and the high level of Th1 could predict better clinical outcomes of chemotherapy.
T cell senescence: a new perspective on immunotherapy in lung cancer

Mengge Huang,Yuetong Wang,Liguang Fang,Cun Liu,Fubin Feng,Lijuan Liu,Changgang Sun

DOI: https://doi.org/10.3389/fimmu.2024.1338680

IF: 7.3

2024-02-13

Frontiers in Immunology

Abstract:T cell senescence is an indication of T cell dysfunction. The ability of senescent T cells to respond to cognate antigens is reduced and they are in the late stage of differentiation and proliferation; therefore, they cannot recognize and eliminate tumor cells in a timely and effective manner, leading to the formation of the suppressive tumor microenvironment. Establishing methods to reverse T cell senescence is particularly important for immunotherapy. Aging exacerbates profound changes in the immune system, leading to increased susceptibility to chronic, infectious, and autoimmune diseases. Patients with malignant lung tumors have impaired immune function with a high risk of recurrence, metastasis, and mortality. Immunotherapy based on PD-1, PD-L1, CTLA-4, and other immune checkpoints is promising for treating lung malignancies. However, T cell senescence can lead to low efficacy or unsuccessful treatment results in some immunotherapies. Efficiently blocking and reversing T cell senescence is a key goal of the enhancement of tumor immunotherapy. This study discusses the characteristics, mechanism, and expression of T cell senescence in malignant lung tumors and the treatment strategies.

immunology
Quantitative evaluation of the circulatory adjustment of splenectomized dogs to hemorrhage.

S. Chien

DOI: https://doi.org/10.1152/AJPLEGACY.1958.193.3.605

1958-06-01

Abstract:Controlled, single hemorrhages were carried out in splenectomized dogs (5–49% of blood volume) and sympathectomized-splenectomized dogs (5–32% of blood volume). A linear relationship exists between the degree of hemodilution and the amount of hemorrhage in both groups. Sympathetic activity aids in the fluid replacement after hemorrhage. In the sympathectomized-splenectomized dogs, the relationship between arterial pressure and blood volume reduction seems to be nonlinear. Arterial pressure of the splenectomized dogs does not decrease until blood volume reduction is more than 10%. Thereafter it decreases linearly with increasing volume reduction which is still compatible with life. In hemorrhages between 10 and 40% of blood volume, the roles played by sympathetic activity and hemodilution in the maintenance of arterial pressure are of about equal importance. The increase in heart rate after hemorrhage has S-shaped relationship to both blood volume reduction and arterial pressure decrease in dogs with or without sympathetic nervous system. The maximum heart rate displayed by sympathectomized dogs after hemorrhage (about 120 beats/min.) is much less than that of the dogs with sympathetic system intact (about 215 beats/min.). The activation of sympathetic activity is not fully achieved immediately after hemorrhage.

Serious herpes zoster in rheumatoid arthritis under anti-interleukin-6 receptor antibody.

The evolution of T-cell receptor repertoire in different stages of non-small cell lung cancer

Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues

Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing

Association of the T-cell Receptor Landscape with Survival in Non-Small Cell Lung Cancer.

Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression

Characterization of T-cell Receptor Repertoire and Correlation with Tumor Mutational Landscape in Lung Cancer.

Functional status and spatial interaction of T cell subsets driven by specific tumor microenvironment correlate with recurrence of non-small cell lung cancer

Single-Cell Transcriptomics of Immune Cells Reveal Diversity and Exhaustion Signatures in Non-Small-Cell Lung Cancer

Deciphering the Immune–Tumor Interplay During Early-Stage Lung Cancer Development via Single-Cell Technology

[Effect of growing location on sensory properties and nutritional characteristics of black beans (Phaseolus vulgaris L.)].

MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer

Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer

Functionally Impaired Follicular Helper T Cells Induce Regulatory B Cells and CD14(+) Human Leukocyte Antigen-Dr- Cell Differentiation in Non-Small Cell Lung Cancer

Heterogeneity of lymphocyte subsets in predicting immune checkpoint inhibitor treatment response in advanced lung cancer: an analysis across different pathological types, therapeutic drugs, and age groups

Comprehensive Analysis of T-cell Receptor Sequencing in Resectable Squamous Cell Lung Cancer Patients with Neoadjuvant Therapy of PD-1 Inhibitor and Chemotherapy.

Cellular dynamics in tumour microenvironment along with lung cancer progression underscore spatial and evolutionary heterogeneity of neutrophil

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Immunomodulatory Effects of Chemotherapy on Blood Lymphocytes and Survival of Patients with Advanced Non-Small Cell Lung Cancer

T cell senescence: a new perspective on immunotherapy in lung cancer

Quantitative evaluation of the circulatory adjustment of splenectomized dogs to hemorrhage.